Polycystic ovary syndrome (PCOS), one of the most common endocrine disturbances, affects 6% to 10% of fertile women 1 and is characterized by irregular menstruation, oligoovulation or anovulation, and hyperandrogenism. 2 PCOS often presents an increased prevalence of early complications such as fertility and obstetric outcomes, and late complications such as cardiovascular, metabolic, and oncologic diseases.
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had received singleton pregnancy by ovulation induction with clomiphene, letrozole, or human menopausal gonadotropin were enrolled and followed up for 6 weeks after delivery. The diagnosis of PCOS was made according to the Rotterdam criteria (2003) , and at least two of the following three criteria were met: clinical and/or biochemical signs of hyperandrogenism, oligoovulation and/or anovulation, and polycystic ovary on ultrasonography, with the exclusion of any related diseases, such as adrenal congenital hyperplasia, Cushing syndrome, androgen-secreting tumors, Hashimoto's thyroiditis, hyperthyroidism, or hypothyroidism. 6 Infertility was diagnosed according to the definition of the World Health Organization (WHO) as the inability to conceive despite regular sexual intercourse over 1 year without the use of any contraceptive methods. 7 PE was diagnosed on the basis of the new onset of hypertension (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg) and either proteinuria (urine protein ≥0.3 g/24 h) or end organ dysfunction or both after 20 weeks of gestation in a previously normotensive woman. 8 Patients did not take any contraceptives or other drugs in 3 months before ovulation induction. Patients who had diabetes mellitus or hypertension or any other chronic diseases before conception were excluded.
| Clinical assessment
Prior to ovulation induction, all data of anthropometric measurements were collected, including weight, height, waist and hip circumference, sex hormones such as follicle-stimulating hormone (FSH) (mIU/mL), luteinizing hormone (LH) (mIU/mL), prolactin (PRL) (ng/mL), estradiol (E 2 ) (pg/mL), progesterone (ng/mL), total testosterone (TT) (ng/mL), dehydroepiandrosterone sulfate (DHEA-S) (μg/dL), SHBG (nmol/L),
and TGs (mmol/L) obtained in the morning of the third to fifth day of the menstrual cycle, as well as glucose and insulin levels after an oral glucose tolerance test (OGTT) (75-g glucose, 3-hour load).
All blood samples were analyzed at the laboratory of Obstetrics and Gynecology Hospital of Fudan University. SHBG and insulin levels were quantified using a Modular E170 analyzer (Roche Diagnostics, Mannheim, Germany) after calibration with the international standard preparation 95/560, with the within-run coefficient of variation 1.0%
(at 21 nmol/L). Glucose and TG levels were measured using a Hitachi 7180 automatic biochemical analyzer (Hitachi, Tokyo, Japan). FSH, LH, PRL, E 2 , progesterone, T, and DHEA-S levels were determined using a Beckman DxI800 immune analyzer (Beckman, Pasadena, CA Transvaginal sonography was performed to diagnose PCOS and observe the number and size of the follicles in both ovaries using an Aloka SSD 5500 ultrasonoscope (Aloka Inc, Tokyo, Japan). Optimal follicular growth was monitored in subsequent cycles until ovulation.
| Ethics statement
The current study was approved by the ethics committee of Obstetrics and Gynecology Hospital, Fudan University. All patients signed written consent giving permission to use their results without mentioning their names in the current study.
| Statistical analysis
All collected data were analyzed with SPSS software, Figure 2 ). The optimal cutoff values were not calculated because of the limited group size.
| RESULTS

| DISCUSSION
The current study showed a strong association of prepregnancy SHBG, BMI, and insulin levels with the development of PE in infertile patients with PCOS, where preconception SHBG levels seemed to contribute the best predictive value according to both logistic regression analysis and ROC analysis.
As indicated by literature review, we are the first to explore the risk value of preconception SHBG levels for PE in women with PCOS, although it has been reported to be predictive of gestational diabetes mellitus in patients with PCOS. [11] [12] [13] [14] According to a prospective study, the association between the first-trimester SHBG and PE remained significant (per 100-nmol/L increase; OR, 0.66; 95% CI, 0.47-0.92 [P=.01]). 15 Moreover, a low preconception SHBG level might also promote the development of PE in patients with PCOS, as reported by another prospective study. 16 The researchers reconstructed associative networks, representing molecular genetic interactions between genes and comorbid disease pairs, including PE, diabetes mellitus, gestational diabetes, and obesity, and found that SHBG was one of the risk gene factors. 16 The pathogenesis, however, remains unknown. In 1998, Sherif and colleagues 17 found a significant negative correlation of SHBG and the sum of insulin during SHBG was the major transport protein in plasma for testosterone in women, of which 95% was SHBG-bound. 19 It is well recognized that reduced SHBG levels in the plasma leads to more unbound testosterone and subsequent hyperandrogenism. Carlsen and colleagues 20 reported that maternal androgen levels were already elevated in the early second trimester among women who eventually developed PE (OR, 3.7; 95% CI, 1.3-10.4). Naver and colleagues 21 reported that the overall risk of PE was significantly increased in a hyperandrogenic subsample of women with PCOS (OR, 2.41; 95% CI, 1.26-4.58
[P<.001]). Although TT levels before pregnancy are not comparative between infertile PCOS women with PE and without PE, we indeed found that the value of preconception FAI in women with PCOS was almost two times of that in women without PE, which indicated that a low SHBG level might play an indirect role in the pathogenesis of PE in PCOS. As a result, studies tended to use low SHBG levels as a marker of IR in both cardiovascular disease 17 and in PE. 15, 20 However, it remains unknown whether there is a direct correlation between SHBG and PE in PCOS.
We found that preconception BMI and INS120 also contributed to According to a recently reported meta-analysis on whether IR/insulin sensitivity was impaired in obese/nonobese patients with PCOS and obese/nonobese healthy controls, obese patients with PCOS were found statistically to have the highest IR; nonobese and non-PCOS women to have the highest insulin sensitivity; and nonobese PCOS and obese and non-PCOS women to be between this range, with a lower level of IR than obese patients with PCOS and lower insulin sensitivity than nonobese and non-PCOS patients. 24 A higher BMI might represent more severe IR and therefore women with PCOS may be more susceptible to PE.
Unfortunately, the prevalence of IR accounts for about 50% to 60%
of PCOS cases. 25 It was reported that women with prepregnancy IR were more likely to develop PE (8.4% vs 4.2%, P<.05) than controls. 26 However, we did not find a statistically significant difference of preconception HOMA-IR between PE and non-PE PCOS women after adjusting for BMI in the current study. On the other hand, we found that preconception INS120 was significantly correlated with PE in the infertile women with PCOS, which seemed to be a bigger risk factor when compared with HOMA-IR. Hyperinsulinism, therefore, can also play an important role in the development of PE.
| Limitations
The prospective study had a limitation of group size and the optimal cutoff values failed to be calculated. 
| CONCLUSIONS
